Medicine
Refining Processes for the Co-Development of Genome-Based Therapeutics and Companion Diagnostic Tests
Workshop Summary
by Sarah H. Beachy, Samuel G. Johnson, Steve Olson, and Adam C. Berger, Rapporteurs; Roundtable on Translating Genomic-Based Research for Health; Board on Health Sciences Policy; Institute of Medicine
Description
Many drug developers have examined new strategies for creating efficiencies in their development processes, including the adoption of genomics-based approaches. Genomic data can identify new drug targets for both common and rare diseases, can predict which patients are likely to respond to a specific treatment, and has the potential to significantly reduce the cost of clinical trials by reducing the number of patients that must be enrolled in order to demonstrate safety and efficacy. A key component of the approval of targeted therapeutics is the ability to identify the population of patients who will benefit from treatment, and this has largely hinged on the co-development and co-submission to the FDA of a companion diagnostic test.The co-development process, or the development of the test and drug for the simultaneous submission to FDA, has led to a major alteration in the way that drugs are being developed, with traditionally separate entities-pharmaceutical and diagnostic companies-now working in close collaboration. Refining Processes for the Co-Development of Genome-Based Therapeutics and Companion Diagnostic Tests is the summary of a workshop held by the Roundtable on Translating Genomic-Based Research for Health on February 27, 2013 to examine and discuss challenges and potential solutions for the codevelopment of targeted therapeutics and companion molecular tests for the prediction of drug response. Prior to the workshop, key stakeholders, including laboratory and medical professional societies, were individually asked to provide possible solutions to resolve the concerns raised about co-development of companion diagnostic tests and therapies. Workshop speakers were charged with addressing these solutions in their presentations by providing insight on (1) whether the proposed solutions address the problems described, (2) whether there are other solutions to propose, and (3) what steps could be taken to effectively implement the proposed solutions.
More Information
Rights Information
All rights held excluding Japan, China, Republic of Korea
Marketing Information
http://www.nap.edu/18617
National Academies Press
The National Academies Press (NAP) publish the reports of the National Academies of Sciences, Engineering and Medicine. They published more than 200 books a year on a wide range of topics.
View all titlesBibliographic Information
- Publisher National Academies Press
- Publication Date April 2014
- Orginal LanguageEnglish
- ISBN/Identifier 9780309298216
- Publication Country or regionUnited States
- FormatPaperback
- Primary Price 35 USD
- Pages102
- ReadershipProfessional and scholarly
- Publish StatusPublished
- Dimensions9 x 6 inches
- Biblio NotesRelated Digital edition - 9780309298223 . Copyright year 2014.
Thank you for proceeding with this offer.
National Academies Press has chosen to review this offer before it proceeds.
You will receive an email update that will bring you back to complete the process.
You can also check the status in the My Offers area
National Academies Press has chosen to review this offer before it proceeds.
You will receive an email update that will bring you back to complete the process.
You can also check the status in the My Offers area
![Loading...](/Content/images/please-wait.gif)
Please wait while the payment is being prepared.
Do not close this window.
(c) Copyright 2024 - Frankfurt Rights. All Right Reserved